Spyre Therapeutics, Inc. (SYRE)
| Market Cap | 6.52B +624.2% |
| Revenue (ttm) | n/a |
| Net Income | -148.70M |
| EPS | -2.17 |
| Shares Out | 86.84M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 840,579 |
| Open | 73.10 |
| Previous Close | 73.10 |
| Day's Range | 72.40 - 75.91 |
| 52-Week Range | 12.29 - 76.00 |
| Beta | 3.13 |
| Analysts | Strong Buy |
| Price Target | 89.08 (+18.7%) |
| Earnings Date | May 5, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $89.08, which is an increase of 18.70% from the latest price.
News
Spyre Therapeutics price target raised to $97 from $64 at Citi
Citi analyst Samantha Semenkow raised the firm’s price target on Spyre Therapeutics (SYRE) to $97 from $64 and keeps a Buy rating on the shares.
Spyre Therapeutics price target raised to $107 from $92 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Spyre Therapeutics (SYRE) to $107 from $92 and keeps a Buy rating on the shares.
Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)
“With our first Phase 2 readout of the year supporting a potential best-in-class profile for SPY001 in IBD, we have begun to deliver on the promise of what we believe
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announ...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibo...
Spyre Therapeutics price target raised to $95 from $64 at JonesResearch
JonesResearch raised the firm’s price target on Spyre Therapeutics (SYRE) to $95 from $64 and keeps a Buy rating on the shares after the company reported the SPY001 monotherapy topline
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and anti...
Spyre Therapeutics 6.5M share Secondary priced at $62.00
The deal size was increased to $403M in common stock from $300M in common stock. Jefferies, Goldman Sachs, Evercore ISI and Guggenheim acted as joint book running managers for the
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineeri...
Spyre Therapeutics price target raised to $90 from $65 at Baird
Baird raised the firm’s price target on Spyre Therapeutics (SYRE) to $90 from $65 and keeps an Outperform rating on the shares. The firm updated its model as its SPY001
Spyre Therapeutics price target raised to $90 from $50 at Wells Fargo
Wells Fargo raised the firm’s price target on Spyre Therapeutics (SYRE) to $90 from $50 and keeps an Overweight rating on the shares. With SPY001 showing significantly better efficacy at
Spyre Therapeutics price target raised to $88 from $55 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Spyre Therapeutics (SYRE) to $88 from $55 and keeps a Buy rating on the shares. The firm cites the company’s positive topline
Spyre Therapeutics announces $300M offering of common stock
Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of $300M of shares of its common stock. Jefferies, Goldman Sachs & Co., Evercore ISI, and Guggenheim Securitie...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineeri...
Spyre Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Spyre Therapeutics (SYRE) with a Strong Buy rating and $80 price target Spyre is developing next-generation, long-acting antibodies for validated targets, says the ...
Spyre Therapeutics price target raised to $80 from $65 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Spyre Therapeutics (SYRE) to $80 from $65 and keeps an Outperform rating on the shares. Spyre’s SPY001 monotherapy surpassed histor...
Spyre data ‘exceptional,’ but combos could enable ‘dominance,’ says TD Cowen
TD Cowen says Spyre Therapeutics (SYRE)’ webcast “strengthened our confidence in an already great dataset” for SPY001, but adds that both management and the firm remains bullish on combos, where
Spyre Therapeutics price target raised to $106 from $49 at Leerink
Leerink raised the firm’s price target on Spyre Therapeutics (SYRE) to $106 from $49 and keeps an Outperform rating on the shares. The firm notes the company hosted an investor
Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
Leerink notes Spyre Therapeutics (SYRE) announced positive topline results from the open-label SPY001 monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis. Overall, the firm ...
Leerink sees Spyre’s SPY001 Phase 2 Data as incrementally positive for Oruka
Leerink analyst David Risinger views Spyre Therapeutics’ (SYRE) positive topline results from the open-label SPY001 monotherapy cohort in the Phase 2 SKYLINE platform trial in ulcerative colitis as in...
Leerink remains bullish on Spyre after SPY001 delivers ‘striking’ Phase 2 Data
Leerink notes Spyre Therapeutics (SYRE) announced positive topline results from the open-label SPY001 monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis. Overall, the firm ...
Spyre Therapeutics price target raised to $98 from $70 at BTIG
BTIG analyst Julian Harrison raised the firm’s price target on Spyre Therapeutics (SYRE) to $98 from $70 and keeps a Buy rating on the shares. Phase 2 Part A data
Spyre Therapeutics price target raised to $85 from $47 at Jefferies
Jefferies raised the firm’s price target on Spyre Therapeutics (SYRE) to $85 from $47 and keeps a Buy rating on the shares. The firm said it got the first dataset
Spyre Therapeutics Transcript: Study result
SPY001 demonstrated strong efficacy and safety in the SKYLINE Part A induction study for ulcerative colitis, achieving high rates of clinical remission and endoscopic improvement. Results exceeded benchmarks from precedent trials, supporting SPY001 as a promising monotherapy and combination backbone, with further global studies underway.
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p